Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in locally advanced and metastatic secondary angiosarcoma
2020-005465-13Phase 2Completed
- Sponsor
- Radboudumc
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in angiosarcoma, sponsored by Radboudumc. Primary endpoint: Overall response rate after 24 weeks. Started Oct 2021; status: completed.
02
Drugs
cemiplimab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on 2020-005465-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005465-13.